Cibc World Market Inc. Has $41.98 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Cibc World Market Inc. raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 40.0% in the 4th quarter, HoldingsChannel.com reports. The fund owned 342,011 shares of the biopharmaceutical company’s stock after purchasing an additional 97,779 shares during the quarter. Cibc World Market Inc.’s holdings in Gilead Sciences were worth $41,978,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the stock. Ares Financial Consulting LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $28,000. Financial Consulate Inc. increased its holdings in Gilead Sciences by 85.8% in the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares during the last quarter. North Star Investment Management Corp. lifted its stake in Gilead Sciences by 54.8% in the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 86 shares during the period. BOCHK Asset Management Ltd acquired a new position in Gilead Sciences in the fourth quarter valued at about $31,000. Finally, Godfrey Financial Associates Inc. bought a new position in Gilead Sciences during the fourth quarter worth about $34,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.1%

NASDAQ GILD opened at $129.18 on Friday. Gilead Sciences, Inc. has a one year low of $104.46 and a one year high of $157.29. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The firm has a market cap of $160.39 billion, a P/E ratio of 17.60 and a beta of 0.31. The stock’s 50-day moving average is $134.56 and its 200-day moving average is $134.34.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. During the same period in the previous year, the firm earned $1.81 EPS. Gilead Sciences’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.79 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio is 44.69%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Oppenheimer boosted their target price on Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. Daiwa Securities Group reduced their price objective on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 19th. Argus boosted their price objective on shares of Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Finally, Leerink Partners cut their target price on shares of Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Twenty-six equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $156.93.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead and Lakefront completed the acquisition of Ouro Medicines, expanding the company’s inflammation pipeline and adding gamgertamig, a potential first-in-class T cell engager for autoimmune diseases. This can support the stock by broadening long-term growth opportunities. Article Title
• Positive Sentiment: Gilead reported positive Phase 3 IDEAL trial results for Livdelzi in primary biliary cholangitis, including improved ALP normalization, which strengthens the case for a larger liver disease franchise and potential regulatory momentum. Article Title
• Positive Sentiment: Additional coverage highlighted favorable Livdelzi data and the company’s expanding liver and oncology footprint, which may reinforce confidence in Gilead’s growth pipeline. Article Title
• Neutral Sentiment: Coverage also noted that Gilead is drawing investor attention and being compared with other healthcare names, but these articles are more commentary than a direct new catalyst. Article Title
• Negative Sentiment: CEO Daniel Patrick O’Day sold 15,000 shares under a pre-arranged trading plan. While routine, insider selling can still weigh on sentiment for some investors. Article Title

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the transaction, the insider directly owned 125,779 shares of the company’s stock, valued at approximately $16,513,524.91. This represents a 18.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $132.27, for a total value of $396,810.00. Following the transaction, the chief financial officer owned 173,191 shares of the company’s stock, valued at approximately $22,907,973.57. This trade represents a 1.70% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 68,000 shares of company stock valued at $9,047,570 over the last quarter. Corporate insiders own 0.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.